Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology
|
| gptkbp:aimsTo |
reduce toxicity
|
| gptkbp:associated_with |
advanced therapeutic strategies
reduced immunogenicity |
| gptkbp:basedOn |
human IgG1 framework
|
| gptkbp:develops |
engineered monoclonal antibodies
|
| gptkbp:enhances |
antibody half-life
|
| gptkbp:future_plans |
treat various cancers
|
| gptkbp:has_a_focus_on |
biopharmaceutical research
biomedical engineering research clinical research efforts |
| gptkbp:hasPrograms |
immunotherapy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xencor's XmAb technology
|
| gptkbp:improves |
efficacy of therapeutics
|
| gptkbp:includes |
gptkb:XmAb®_bispecific_antibodies
|
| gptkbp:is_a_key_component_of |
Xencor's_business_strategy
|
| gptkbp:is_a_platform_for |
next-generation therapeutics
|
| gptkbp:is_a_subject_of |
scientific publications
patent applications |
| gptkbp:is_aimed_at |
enhancing therapeutic index
|
| gptkbp:is_characterized_by |
modular design
high specificity |
| gptkbp:is_designed_to |
immune response
patient outcomes therapeutic efficacy combination therapies treatment regimens target multiple antigens |
| gptkbp:is_evaluated_by |
clinical trials
|
| gptkbp:is_expected_to |
drive future growth
|
| gptkbp:is_involved_in |
targeted therapy development
biologic drug development |
| gptkbp:is_known_for |
flexibility in design
its modularity its ability to target multiple pathways |
| gptkbp:is_linked_to |
improved safety profiles
|
| gptkbp:is_part_of |
Xencor's_intellectual_property_portfolio
Xencor's_product_pipeline Xencor's_research_initiatives Xencor's_strategic_collaborations Xencor's_therapeutic_offerings |
| gptkbp:is_recognized_for |
its versatility
innovative approaches its innovative design principles its contribution to cancer therapy. |
| gptkbp:is_supported_by |
scientific research
|
| gptkbp:is_used_in |
pharmaceutical companies
cancer treatment preclinical studies autoimmune disease treatment personalized medicine approaches customized therapies therapeutic antibody development |
| gptkbp:isUsedFor |
other therapeutic modalities
|
| gptkbp:leadership |
biotherapeutics innovation
|
| gptkbp:produces |
gptkb:Xencor,_Inc.
|
| gptkbp:utilizes |
Fc domain modifications
|